Trump administration cuts off Medicaid and CHIP funding for gender transition procedures on minors

The Trump administration finalized a rule barring Medicaid and the Children's Health Insurance Program from paying for puberty blockers, cross-sex hormones, and surgeries for minors, a move that effectively shuts the federal spigot on taxpayer-funded gender transition treatments for children.

HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz announced the policy on Tuesday, framing it as the product of a sweeping federal review that found the procedures carry serious risks and rest on thin clinical evidence. The final rule, issued by the Centers for Medicare and Medicaid Services, takes effect October 13, 2026, and includes a tapering-off period of up to six months for children already receiving hormone therapy through Medicaid or CHIP.

Kennedy did not hold back in his statement. Breitbart News reported the HHS secretary's announcement:

"Today, we are ending federal taxpayer funding for sex-rejecting procedures on children. These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve."

The rule covers three categories: puberty blockers, cross-sex hormones, and surgical interventions. Mental health services remain covered, a distinction the administration drew explicitly in the final rule text. CMS stated the banned procedures "can result in irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects."

CMS spent $30 million on these procedures in a single year

The financial scope of the federal government's role came into sharper focus through additional reporting. CMS spent $30 million in Medicaid payments in 2023 alone for gender transition treatments for minors, with an estimated $250 million projected over the next decade, the Washington Examiner reported. That figure puts a concrete price tag on what the administration now calls an unproven medical experiment funded by taxpayers.

Dr. Oz reinforced the administration's rationale in his own statement:

"Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these sex-rejecting procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish."

The rule carries enormous practical weight because nearly every hospital in the country accepts Medicare or Medicaid funding. Cutting off that funding stream for facilities performing these procedures on minors amounts to a de facto federal prohibition, not through a congressional ban, but through the government's power of the purse.

The administration's broader crackdown extends beyond CMS. Kennedy signed a formal declaration finding that gender transition procedures for minors "do not meet professionally recognized standards of care." The FDA separately issued warning letters to 12 manufacturers of breast binders for illegally marketing their products to treat gender dysphoria in children, the New York Post reported. Those letters carry the threat of product seizures if manufacturers do not comply.

HHS review cited the UK's Cass Report as key evidence

CMS pointed to a review of national and international research conducted by HHS that found "significant evidence gaps and serious safety concerns" surrounding gender transition treatments for children. The agency specifically cited the United Kingdom's Cass Report, a landmark independent review commissioned by Britain's National Health Service, which found limited and inconclusive evidence supporting the safety of such interventions for minors.

The administration also pointed to policy shifts by the Society of Plastic Surgeons and actions taken by other countries, including Sweden, as evidence that its position is "increasingly reflected" within the medical community. The trend is not limited to the federal government. President Trump noted in a Truth Social post that "dozens of U.S. hospitals have already ended this so-called 'gender-affirming care'" over the past year and a half of administration pressure.

That broader pattern tracks with other recent federal actions. A federal appeals court recently cleared Florida's lawsuit against a major pediatrics group over youth gender procedures, adding legal momentum to the pushback against these treatments.

Kennedy went further in characterizing the medical establishment's role. In remarks reported by Fox News, the HHS secretary accused hospitals of profiting from vulnerable children:

"Hospitals rake in millions of dollars by convincing boys and girls that a lifetime of off-label prescriptions for estrogen and testosterone blockers, chest reconstruction, surgeries, and more are the only way to achieve true happiness and belonging in life. It's wrong."

He added bluntly: "This is not medicine, it is malpractice."

Trump directed the move and tied it to midterm elections

President Trump made clear the policy came at his direction. In a lengthy Truth Social post, he framed the decision as both a child-protection measure and a political marker ahead of the November midterm elections.

"Today, at my direction, Dr. Mehmet Oz announced that Medicaid will NO LONGER fund gender transition surgeries and hormones for minors. We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies."

Trump urged voters to "remember this when you are casting your vote in the Midterm Elections in November." The president drew a direct contrast with Democrats, accusing the opposing party of supporting these procedures for children who are not yet old enough to vote.

The funding rule is part of a broader pattern of the Trump administration using executive authority to cut off federal dollars from programs it views as harmful or wasteful. HHS recently terminated $67 million in teen pregnancy grants to Planned Parenthood and dozens of other organizations over explicit content concerns, another example of the administration wielding the funding lever to enforce its policy priorities.

LGBTQ groups vow legal challenges

The policy has drawn fierce opposition. Human Rights Campaign President Kelley Robinson accused the administration of targeting transgender youth and their families. AP News reported Robinson's response:

"The Trump administration is terrorizing trans youth and their families with these kinds of actions, and it has to stop."

LGBTQ+ advocacy groups have vowed to pursue legal challenges to the rule. But the administration has layered its approach. Beyond the CMS funding ban, HHS has also proposed reversing the Biden administration's classification of gender dysphoria as a disability under Section 504 of the Rehabilitation Act, the 1973 federal law that prohibits discrimination based on disability in programs receiving federal funding. That reclassification, National Review reported, would remove another legal foothold that advocates have used to argue these treatments must be covered.

The six-month tapering-off period for children currently receiving hormone therapy through Medicaid or CHIP provides a transition window. Coverage for those patients phases out by April 2027. But the rule draws a hard line: no new federal funding for puberty blockers, cross-sex hormones, or surgeries for minors after October 13, 2026.

Several significant questions remain unanswered. The rule's text has not been publicly linked in available reporting, and it is unclear how many children currently receive Medicaid- or CHIP-funded hormone therapy nationwide. Whether the rule applies uniformly across all 50 state Medicaid programs, or whether states might seek workarounds, has not been addressed. And the inevitable legal challenges have yet to be filed.

The administration has also shown a willingness to shift decision-making power back to parents on matters of children's health, a theme that runs through multiple recent executive actions. Kennedy and Oz have positioned the gender transition funding ban as consistent with that principle, protecting children from irreversible medical decisions made before they are old enough to fully consent.

Kennedy's HHS report characterized the supporting studies behind gender transition treatments for minors as "low quality." The CMS statement described the procedures as "experimental and life-altering." And the administration backed those words with the one tool that matters most in federal health policy: money.

When the government stops writing the checks, the practice stops, or at least stops being subsidized by the people who never asked to pay for it in the first place.